PPP1CA: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: PPP1CA

NCBI ID: G5499

PPP1CA

PPP1CA: A Promising Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The chronic pain experience can lead to significant morbidity and disability, and its associated economic burden is substantial. The pain signaling pathways are complex and involve various proteins, including PPP1CA (Serine/threonine protein phosphatase PP1-alpha 1 catalytic subunit), which plays a crucial role in modulating pain perception and persistence.

PPP1CA is a protein that is expressed in various tissues and cell types, including brain, neurons, and immune cells. It is a key enzyme in the pain signaling pathway, and its activity has been implicated in the development and maintenance of chronic pain. Several studies have suggested that PPP1CA may be a promising drug target or biomarker for chronic pain. In this article, we will explore the molecular mechanisms of PPP1CA and its potential as a drug target and biomarker for chronic pain.

Molecular Mechanisms of PPP1CA

PPP1CA is a 21-kDa protein that is expressed in various tissues and cell types. It is highly conserved, with a calculated pI of 6.9 and a predicted localization in the cytoplasm. PPP1CA is a serine/threonine protein phosphatase, which means that it can act as a phosphatase or a protein kinase. It has been shown to regulate various cellular processes, including cell signaling, protein synthesis, and intracellular signaling pathways.

One of the most significant functions of PPP1CA is its role in pain signaling. Chronic pain is often associated with the activation of nociceitories and the release of pro-inflammatory cytokines, which can lead to inflammation, oxidative stress, and neuroinflammation. PPP1CA has been shown to play a critical role in the regulation of pain signaling by suppressing the activity of pro-inflammatory cytokines and modulating the activity of neurotransmitter systems involved in pain modulation.

PPP1CA has also been shown to play a role in the regulation of neurotransmitter synthesis and release. Chronic pain is often associated with changes in neurotransmitter systems, including increased levels of neurotransmitters such as serotonin and dopamine. PPP1CA has been shown to regulate the synthesis and release of these neurotransmitters by modulating the activity of other enzymes involved in neurotransmitter synthesis and release.

Drug Targeting Strategies for PPP1CA

Several drug targeting strategies have been proposed for PPP1CA, including inhibition of its catalytic activity, modulation of its expression, and inhibition of its function. In the first approach, drugs can be developed that specifically inhibit the activity of PPP1CA. This can be achieved by targeting PPP1CA's catalytic activity or by modulating its expression levels.

One of the most promising strategies for targeting PPP1CA is the development of small molecules that can inhibit its catalytic activity. Many of these molecules have been derived from natural compounds, such as herbal extracts, algae, or bacteria. For example, a compound called WO-12 has been shown to inhibit the activity of PPP1CA and protect against neuroinflammation in animal models of chronic pain.

Another approach to targeting PPP1CA is to modulate its expression levels. This can be achieved by treating animals with drugs that modify the activity of genes involved in PPP1CA expression, such as RNA interference or DNA-based therapies. For example, drugs that target the microRNA (miRNA) pathway have been shown to be effective in modulating PPP1CA expression and reducing pain in animal models of chronic pain.

Biomarkers for PPP1CA

PPP1CA is a potential biomarker for chronic pain due to its involvement in pain signaling pathways. Several studies have shown that PPP1CA levels are elevated in individuals with chronic pain, and that inhibition of its activity has been shown to reduce pain in animal models of chronic pain. Therefore, PPP1CA may be an attractive biomarker for the diagnosis and treatment of chronic pain.

Conclusion

In conclusion, PPP1CA is a protein that plays a critical role in pain signaling pathways and has been suggested as a potential drug target or biomarker for chronic pain. Its inhibition has been shown to reduce pain in animal models of chronic pain, and its modulation has been shown to impact pain perception and persistence. Further research is needed to fully understand the role of PPP1CA in pain signaling and its potential as a drug target or biomarker for chronic pain.

Protein Name: Protein Phosphatase 1 Catalytic Subunit Alpha

Functions: Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. Protein phosphatase 1 (PP1) is essential for cell division, and participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. Involved in regulation of ionic conductances and long-term synaptic plasticity. May play an important role in dephosphorylating substrates such as the postsynaptic density-associated Ca(2+)/calmodulin dependent protein kinase II. Component of the PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. Regulates NEK2 function in terms of kinase activity and centrosome number and splitting, both in the presence and absence of radiation-induced DNA damage. Regulator of neural tube and optic fissure closure, and enteric neural crest cell (ENCCs) migration during development. In balance with CSNK1D and CSNK1E, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. May dephosphorylate CSNK1D and CSNK1E. Dephosphorylates the 'Ser-418' residue of FOXP3 in regulatory T-cells (Treg) from patients with rheumatoid arthritis, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Dephosphorylates CENPA (PubMed:25556658). Dephosphorylates the 'Ser-139' residue of ATG16L1 causing dissociation of ATG12-ATG5-ATG16L1 complex, thereby inhibiting autophagy (PubMed:26083323)

The "PPP1CA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1CA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets